CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 901–1,000 of 1,725
Dave, P., Anand, P., Kothawala, A., Srikaram, P., SHASTRI, D. D., Uddin, A., Bhavsar, J., & Winer, A. (2024) · Cureus · doi:10.7759/cureus.62981 · Cited by 11
“NTLA-2001, a CRISPR-based gene-editing therapy, and Acoramidis, a selective TTR stabilizer, show significant potential in treating ATTR amyloidosis [44, 45].”
BackgroundMethodGene editing in liver diseases
Torella, L., Santana‐Gonzalez, N., Zabaleta, N., & González‐Aseguinolaza, G. (2024) · FEBS Letters · doi:10.1002/1873-3468.14989 · Cited by 9
“This strategy has been employed to treat the aforementioned diseases, utilizing various nuclease editing platforms and delivery vehicles, leading to the first clinical success of gene editing targeting the liver [95].”
CRISPR-based gene therapy for the induction of fetal hemoglobin in sickle cell disease
McManus, M. P., Frangoul, H., & Steinberg, M. H. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2429605 · Cited by 10
“Already, in vivo gene therapy has been efficacious in familial transthyretin ( TTR ) amyloidosis and familial hypercholesterolemia [73,74].”
In vivo gene editing works in humans: Results of a phase 1 clinical trial for TTR amyloidosis
Batista, A. R., & Flotte, T. R. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.014 · Cited by 8
A first step toward in vivo gene editing in patients
Büning, H., & Schambach, A. (2021) · Nature Medicine · doi:10.1038/s41591-021-01476-6 · Cited by 6
CRISPR‐Cas9 Genome Editing of Primary Human Vascular Cells In Vitro
Atri, D. S., Lee‐Kim, V. S., Vellarikkal, S. K., Sias‐Garcia, O., Yanamandala, M., Schniztler, G. R., & Gupta, R. M. (2021) · Current Protocols · doi:10.1002/cpz1.291 · Cited by 7
Zebrafish and idiopathic scoliosis: the ‘unknown knowns’
Liu, Z., Hai, Y., Li, Z., et al. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.01.002 · Cited by 7
Disrupting off-target Cas9 activity in the liver
Dilliard, S. A., & Siegwart, D. J. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00848-8 · Cited by 8
Treating hereditary transthyretin amyloidosis: Present & future challenges.
Echaniz-Laguna, A., Cauquil, C., Labeyrie, C., & Adams, D. (2022) · Revue neurologique (Paris) · doi:10.1016/j.neurol.2022.07.006 · Cited by 7
Current and potential therapeutic strategies for transthyretin cardiac amyloidosis
Williams, M. A. C., Shankar, B., Vaishnav, J., & Ranek, M. J. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1015545 · Cited by 10
“Such a marked reduction in serum TTR levels gives promise that this may be an efficacious and safe method for managing ATTR-CM (Gillmore et al., 2021).”
MethodGene Therapy for Paediatric Homozygous Familial Hypercholesterolaemia
Graves, L. E., Horton, A., Alexander, I. E., & Srinivasan, S. (2023) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.01.017 · Cited by 7
Essawi, K., Hakami, W., Khan, M. B. N., Martin, R., Zeng, J., Chu, R., Uchida, N., Bonifacino, A. C., Krouse, A. E., Linde, N. S., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.04.004 · Cited by 9
“tolerated with sustained editing inferred by the absence of target gene product.(33) In this manner, AAV- and AdV-based Cas9 delivery providing long-term protein expression could be the reason for robust immune system activation.”
BackgroundA Split-Marker System for CRISPR-Cas9 Genome Editing in Methylotrophic Yeasts
Karginov, A. V., Tarutina, M. G., Lapteva, A. R., Pakhomova, M., Galliamov, A. A., Filkin, S. Y., Fedorov, A. N., & Agaphonov, M. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098173 · Cited by 7
“CRISPR-Cas9 based approaches are already in use the therapy of β-thalassemia [11] and transthyretin amyloidosis [12,13].”
BackgroundAlbenque, G., Bézard, M., Kharoubi, M., et al. (2023) · Amyloid · doi:10.1080/13506129.2023.2227322 · Cited by 7
“In this sense, with the rapid development of CRISPR-Cas9 gene editing, this tool could also one day be of potential interest for homozygous patients or their descend-ants [31].”
BackgroundClinical Pharmacology and Translational Considerations in the Development of CRISPR‐Based Therapies
Abdelhady, A. M., Phillips, J. A., Xu, Y., & Stroh, M. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3000 · Cited by 11
“Gillmore et al.8 summarizes the nonclinical data that informed the design of the FIH study for NTLA- 2001.”
InfluentialSelf-citationMesenchymal stem cell engineering by ARCA analog-capped mRNA
Andrzejewska, A., Grzela, R., Stankiewicz-Drogoń, A., Rogujski, P., Nagaraj, S., Darżynkiewicz, E., Łukomska, B., & Janowski, M. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.07.006 · Cited by 8
“There is an explosion in genome editing research,(36) which has been initially clinically translated through mRNA-based in vivo delivery.(37) Notably, genome editing, like our stem cell engineering, also requires a lack of immune activation; therefore, potentially, our findings could be widely applicable to the exciti…”
BackgroundWhat did CRISPR-Cas9 accomplish in its first 10 years?
Khlidj, Y. (2023) · Biochemia Medica · doi:10.11613/bm.2023.030601 · Cited by 10
“ing diseases such as resistant cancers and incurable genetic disorders ultimately demonstrating first of their kind, promising results (7-11).”
BackgroundOptimizing Informed Consent in Cancer Clinical Trials
Perni, S., Jimenez, R., & Jagsi, R. (2023) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2023.06.001 · Cited by 9
Kimura, S., & Harashima, H. (2024) · BioDrugs · doi:10.1007/s40259-024-00647-4 · Cited by 9
“…needs, including gene editing by using clustered regularly interspaced short pal-indromic repeats (CRISPR)/CRISPR associated proteins 9 (Cas9) [11, 12], gene addition/protein replacement by using plasmid DNA (pDNA) [13, 14] or messenger RNA (mRNA) [15, 16], and gene inhibition by using…”
A comprehensive review on the current status of CRISPR based clinical trials for rare diseases
Badwal, A. K., & Singh, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134097 · Cited by 12
In vivo expansion of gene-targeted hepatocytes through transient inhibition of an essential gene
Giorgi, M. D., Park, S. H., Castoreno, A. B., Cao, M., Hurley, A. E., Saxena, L., Chuecos, M. A., Walkey, C. J., Doerfler, A. M., Furgurson, M. N., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adk3920 · Cited by 11
O’Sullivan, G. M., Philips, J. G., Mitchell, H. J., Dornbusch, M., & Rasko, J. E. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.883434 · Cited by 9
First-in-human gene editing for lipid lowering: the initial results
Tual‐Chalot, S., & Stellos, K. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae037 · Cited by 6
Ahammed, M. R., & Ananya, F. N. (2024) · Cureus · doi:10.7759/cureus.63673 · Cited by 9
“A phase 1 clinical study showed a sustained suppression of TTR production after a single infusion, with no significant adverse events reported during short-term follow-up [54].”
BackgroundIn vivo genome editing for inherited retinal disease: Opportunities and challenges
Collin, R. W. J., & Leroy, B. P. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.001 · Cited by 6
The Progress and Promise of Lineage Reprogramming Strategies for Liver Regeneration
Wang, S., Wang, X., & Wang, Y. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101395 · Cited by 7
“74, 79 – 81 Therefore, for in vivo liver reprogramming, LNPs are well-suited for delivering mRNA encoding CRISPR system or speci fi c TFs to hepatocytes to reprogram injured/aging hepatocytes into a proliferation state or alleviate proliferation inhibition caused by liver diseases or injuries.”
BackgroundVázquez-Domínguez, I., Öktem, M., Winkelaar, F. A., Nguyen, T. H., Hoogendoorn, A. D. M., Roschi, E., Astuti, G., Timmermans, R., Suárez-Herrera, N., Bruno, I., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102345 · Cited by 7
“87 Moreover, the PPC model, despite being retina speci fi c, consists of a mixed cell population that is not well de fi ned, and therefore this can lead to variability in Cas9 RNP uptake and ABCA4 expression among different cell lines and batches.”
Liu, Q., Li, X., Xu, H., Luo, Y., Cheng, L., Liang, J., He, Y., Liu, H., Fang, J., & Huang, J. (2025) · Advanced Biotechnology · doi:10.1007/s44307-024-00053-5 · Cited by 6
“…short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9) nuclease sys-tem, widely applied in gene therapy (H. Frangoul et al. 2021; Gillmore et al. 2021; Wei et al. 2019; Wen et al. 2022; Zittersteijn et al. 2020), was guided by single-guide RNA (sgRNA) to generate double-strand…”
Charlesworth, C. T., Homma, S., Amaya, A. K., Dib, C., Vaidyanathan, S., Tan, T.-K., Miyauchi, M., Nakauchi, Y., Suchy, F. P., Wang, S., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101438 · Cited by 8
“28,29 Furthermore, we found that HSCs are preferentially transduced in the BM compared with other cell types, regardless of the delivery route.”
Improving adenine base editing precision by enlarging the recognition domain of CRISPR-Cas9
Gao, S., Weng, B., Wich, D., Power, L. H., Chen, M., Guan, H., Ye, Z., Xu, C., & Xu, Q. (2025) · Nature Communications · doi:10.1038/s41467-025-57154-5 · Cited by 9
Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathy
Ang, S. P., Chia, J. E., & Mukherjee, D. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10502-5 · Cited by 10
“This specificity stems from the optimized sgRNA design pipeline, which excluded candidates with homology to pathogenic TTR variants or single-nucletotide polymorphisms while prioritizing sequences with minimal off-target potential through in vitro genotoxicity screens [7].”
InfluentialGene-based therapies for steatotic liver disease
Iakovleva, V., & de Jong, Y. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.024 · Cited by 9
“160,161 Together, these developments are poised to lead to therapies to “permanently” protect steatotic livers from disease progression, offering transformative benefits to individuals with SLD, particularly those affected early in life.”
Esmaeilzadeh, A., Hadiloo, K., Yaghoubi, S., Makoui, M. H., & Mostanadi, P. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01056-7 · Cited by 8
“Systemic delivery of lipid nanoparticles (LNP) to transfer CRISPR Cas9 (Clustered regularly interspaced short palindromic repeats associated protein9) RNA to the liver decreased the harmful accumulation of misfolded TTR amyloid in patients [ 50 ].”
Weaponizing CRISPR/Cas9 for selective elimination of cells with an aberrant genome
Tavella, S., di Lillo, A., Conti, A., Iannelli, F., Mancheno-Ferris, A., Matti, V., Micco, R. D., & di Fagagna, F. D. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103840 · Cited by 7
Challenges and Future Directions for Next-Generation Drug Delivery Systems
Sarma, L., Singh, S., Anjali, & Dutta, D. (2025) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-4554-3_25 · Cited by 10
RNA-ssisting immunity to heal the heart: a new frontier in therapeutics
Rurik, J. G., Phu, C. L., Mustroph, J., & Buggert, M. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000116 · Cited by 6
“Furthermore, the expression of TTR can be shut off by liver editing to limit the accumulation of amyloid plaques, protecting patients from further disease pathogenesis [168] .”
Zhang, G., Tu, J., Zhang, Y., He, J., Peng, G., Fan, Q., Zhang, Y., Zhang, M., Tan, H., Xu, Y., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102620 · Cited by 8
“28,29 This study focuses on mRNA-based protein replacement therapy.”
Self-citationRNA‐Based Therapeutics: Cutting‐Edge Advances in Clinical Research
Ferreira, D., & Rodrigues, L. R. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500082 · Cited by 7
The path to biotechnological singularity: Current breakthroughs and outlook
Wen, Z., Yang, D., Yang, Y., Hu, J., Parviainen, A., Chen, X., Li, Q., VanDeusen, E. A., Ma, J., & Tay, F. R. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108667 · Cited by 8
Protective antigen–mediated delivery of an anti-CRISPR protein for precision genome editing
Vera, A. O., Truex, N. L., Sreekanth, V., Pentelute, B. L., Choudhary, A., & Raines, R. T. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2426960122 · Cited by 9
“SpCas9 - NLS RNP (20 pmol), targeting the GAPDH gene, and the HiBiT ssODN (80 pmol) were delivered via nucleofection into HEK293T cells (300,000 cells) using an SF Cell Line 4D - Nucleofector X Kit (Lonza, V4SC - 2096, CM - 130 protocol).”
InfluentialDendrimers Improve Apolipoprotein Nanoparticle mRNA Delivery to Immune Cells
Trines, M. M., Hoorn, D., Hofstraat, S. R. J., Zwolsman, R. C., Anbergen, T., Versteeg, I., van Elsas, Y., Deckers, J., Hendrikx, M., Kleuskens, T., et al. (2025) · Advanced Materials · doi:10.1002/adma.202504830 · Cited by 11
The curious case of anti-PEG antibodies
Denman, D. S., & Dalhaimer, P. (2025) · Nanoscale · doi:10.1039/d5nr02301g · Cited by 11
Kansal, R. (2025) · Genes · doi:10.3390/genes16111367 · Cited by 6
“…nanoparticles have been researched as promising non-viral drug delivery vehicles since the first FDA approval given in 2018 to LNPs to deliver a small interfering RNA (siRNA), which was used in the clinical trial for in vivo CRISPR-based gene editing for transthyretin amyloidosis [153,154].”
AI-guided redesign of laboratory-evolved reverse transcriptases enhances prime editing
Tao, Y. A., Sakai, H. A., Jiang, A. Y., Krasnow, N. A., Vaganov, V., Shim, B. H., Barsdale, Z., Pandey, S., Ahmed, N., Na, M., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03149-6 · Cited by 16
Reshetnikov, V. V., Chirinskaite, A. V., Sopova, J. V., Ivanov, R. A., & Леонова, Е. И. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.903812 · Cited by 9
“Untargeting” autoantibodies using genome editing, a proof-of-concept study
Keppeke, G. D., Diogenes, L., Gomes, K., & Andrade, L. E. C. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109343 · Cited by 6
Thevendran, R., & Solayappan, M. (2023) · Biotechnology Journal · doi:10.1002/biot.202300077 · Cited by 7
DANGER analysis: risk-averse on/off-target assessment for CRISPR editing without a reference genome
Nakamae, K., & Bono, H. U. (2023) · Bioinformatics Advances · doi:10.1093/bioadv/vbad114 · Cited by 7
Bortolussi, G., Iaconcig, A., Canarutto, G., Porro, F., Ferrucci, F., Galletta, C., Díaz-Muñoz, C., Rawat, V., Caneva, A. D., Olajide, O. J., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101161 · Cited by 7
“19,20 The required rate of correction varies depending on both the disease type and the presence or absence of growth advantage of the corrected cells.”
BackgroundOut of the dark: the emerging roles of lncRNAs in pain
Habib, A. M., Cox, J. J., & Okorokov, A. L. (2024) · Trends in Genetics · doi:10.1016/j.tig.2024.04.009 · Cited by 6
Advances in CRISPR/Cas systems-based cell and gene therapy
Poddar, A., Ahmady, F., Prithviraj, P., Luwor, R. B., Shukla, R., Polash, S. A., Li, H., Ramakrishna, S., Kannourakis, G., & Jayachandran, A. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.07.005 · Cited by 6
Delivery approaches of immunomodulatory nucleic acids for cancer therapy
Hu, X., Enbar, T., & Tang, L. (2024) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2024.103182 · Cited by 8
Optimizing drug therapies in cardiac amyloidosis.
Younis, M. F., Ogbu, I., & Kalra, D. K. (2024) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2024.108758 · Cited by 6
Amyloids and the Heart: An Update
Triposkiadis, F. K., Briasoulis, Α., & Xanthopoulos, A. V. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237210 · Cited by 8
Nam, H., Xie, K., Majumdar, I., Wang, J., Yang, S., Starzyk, J., Lee, D., Shan, R., Li, J., & Wu, H. (2025) · Nature Communications · doi:10.1038/s41467-025-59790-3 · Cited by 11
Transthyretin amyloid cardiomyopathy: Evolving therapies, expanding hope
Costabel, J. P., Suárez, L. L., Rochlani, Y. M., Masri, A., Slipczuk, L. N., & Berrios, E. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.07.011 · Cited by 8
Édition de gènes in vivo et thérapie génique
Jordan, B. (2021) · médecine/sciences · doi:10.1051/medsci/2021140 · Cited by 6
Büning, H., Fehse, B., Ivics, Z., Kochanek, S., Koehl, U., Kupatt, C., Mussolino, C., Nettelbeck, D. M., Schambach, A., Uckert, W., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29178.hbu · Cited by 7
“105 Short-term in vivo mRNA expression also presents an interesting perspective for passive immunotherapy based on ‘tumor vaccination’.”
Li, F., Song, N., Dong, Y., Li, S., Li, L., Liu, Y., Li, Z., & Yang, D. (2022) · Angewandte Chemie · doi:10.1002/ange.202116569 · Cited by 6
Future Directions in Cardiac Amyloidosis
Trachtenberg, B. H. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1071 · Cited by 6
The promise of gene editing: so close and yet so perilously far
Segal, D. J. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.974798 · Cited by 8
“highly efficient mutation of genes, as in Intellia’s knock-out of TTR for Transthyretin Amyloidosis mentioned above (Gillmore et al., 2021).”
BackgroundMethodDrug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy
Dardiotis, E., & Kyriakides, T. (2022) · Current Neuropharmacology · doi:10.2174/1570159x21666221108094736 · Cited by 7
“In a phase 1 trial, NTLA-2001, a lipid nanoparticle delivery system carrying a single guide RNA targeting the human TTR and the mRNA of Streptococcus pyogenes, CAS9 protein was injected once in six patients with ATTR amyloidosis [80].”
BackgroundTreating Transthyretin Amyloidosis via Adeno-Associated Virus Vector Delivery of Meganucleases
Greig, J. A., Breton, C. A., Ashley, S. N., Martins, K. M., Gorsuch, C. L., Chorazeczewski, J. K., Furmanak, T., Smith, M. K., Zhu, Y., Bell, P. L., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.061 · Cited by 6
“…in which reductions of 87% (range of 80–96%, n = 3 subjects) were achieved in hereditary ATTR patients at day 28 following a dose of 0.3 mg/kg. 18 As with other LNP-based treatments, this approach also required pre-administration of glucocorticoids and anti-histamines; one patient in the…”
InfluentialPrions: a threat to health security and the need for effective medical countermeasures
Lee, Y.-C. J. (2023) · Global Health Journal · doi:10.1016/j.glohj.2023.02.004 · Cited by 6
Pascolo, S. (2023) · European Journal of Immunology · doi:10.1002/eji.202249941 · Cited by 6
Novel Therapeutic Approaches in Inherited Neuropathies: A Systematic Review
Hustinx, M., Shorrocks, A.-M. K., & Servais, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061626 · Cited by 6
“3 mg/kg, single dose, IV CRISPR-Cas9mediated editing of TTR NCT04601051 (phase 1) [54] - Reduction in serum TTR levels at day 28 by 52% in the 0.”
BackgroundGenome editing and cancer therapy: handling the hypoxia-responsive pathway as a promising strategy
Stampone, E., Bencivenga, D., Capellupo, M. C., Roberti, D., Tartaglione, I., Perrotta, S., Ragione, F. D., & Borriello, A. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04852-2 · Cited by 9
mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond
Prakash, S. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00849-1 · Cited by 9
Monitorización de la amiloidosis cardiaca con imagen multimodal
Starr, N., Ioannou, A., & Martinez–Naharro, A. (2023) · Revista Española de Cardiología · doi:10.1016/j.recesp.2023.06.017 · Cited by 6
Utilization of nicking properties of CRISPR-Cas12a effector for genome editing
Kim, C. H., Lee, W.-J., Oh, Y., Lee, Y., Lee, H. K., Seong, J. B., Lim, K., Park, S. J., Huh, J., Kim, Y., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-53648-2 · Cited by 8
“2, 3, 4, 5).”
The Transthyretin Protein and Amyloidosis – An Extraordinary Chemical Biology Platform
Hammarström, P. (2024) · Israel Journal of Chemistry · doi:10.1002/ijch.202300164 · Cited by 7
Get ready for the CRISPR/Cas system: A beginner's guide to the engineering and design of guide RNAs
Ma, S., Lv, J., Feng, Z., Rong, Z., & Lin, Y. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3377 · Cited by 8
“However, in recent clinical trials, CRISPR gene editing technology was seen to be safe and effective for treating these genetic diseases.(180,206) In addition to safety, ethical issues should not be ignored.”
BackgroundSecreted PGK1 and IGFBP2 contribute to the bystander effect of miR-10b gene editing in glioma
Zhang, Y., Rabinovsky, R., Wei, Z., Fatimy, R. E., Deforzh, E., Luan, B., Peshkin, L., Uhlmann, E. J., & Krichevsky, A. M. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.12.018 · Cited by 8
Du, S. W., & Palczewski, K. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230146 · Cited by 6
Cheng, Y., Nocula-Lugowska, G., Ramirez, J. A., Fan, X., Jin, F., Jiang, Z., Bennett, E. M., Li, J., Hokanson, D. E., Grandhi, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.24.568451 · Cited by 5
“To augment FAN1 protein expression in the HdhQ111 mouse model, we also intended to leverage mRNA-LNP platform, which provides an easy means to over-express target protein in animal models, particularly the liver tissue (53).”
MethodLemoine, J., Dubois, A., Dorval, A., Jaber, A., Warthi, G., Mamchaoui, K., Wang, T., Corre, G., Bovolenta, M., & Richard, I. (2024) · Scientific Reports · doi:10.1038/s41598-024-70075-5 · Cited by 9
“The advantage of single sgRNA approach is that, theoretically, it offers higher gene editing efficiency, given the generally low in vivo efficiency of CRISPR cargo delivery (even lower for co-delivery), and a reduced probability of off-target effects 35,36 .”
BackgroundXie, J., Dunyak, M. T., Hanna, P., Nan, A. X., Estes, B., Cochrane, J. C., Wu, S., Wang, J., McGinnis, C., Wang, Q., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.12.617700 · Cited by 6
Self-citationPardi, N., & Ivics, Z. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.06.011 · Cited by 5
Li, C., Song, Z., Huang, X., Zheng, Y., Nong, C., Jiang, T., Li, Z., Liu, H., & Yi, Z. (2025) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2025.126265 · Cited by 5
The CRISPR-Cas revolution in head and neck cancer: a new era of targeted therapy
Hashemi, M., Khanaghah, X. M., & Nahand, J. S. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01612-2 · Cited by 5
“Electroporation of RNPs targeting TP53 in HNC organoids achieved 95% knockout rates within 24 h, enabling rapid functional studies (Zhou et al. 2023).”
Qin, J., Yang, Q., Ullate‐Agote, A., Sampaio‐Pinto, V., Florit, L., Dokter, I., Mathioudaki, C., Middelberg, L., Montero‐Calle, P., Aguirre‐Ruiz, P., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04464-6 · Cited by 7
Duca, F., Poledniczek, M., Kronberger, C., et al. (2025) · European Radiology · doi:10.1007/s00330-025-11792-x · Cited by 5
CRISPR-Cas technologies: Emerging tools from research to clinical application
Hyeon, H., Hwang, S., Luo, Y., Shin, E., Yeom, J., Kim, H., Ryu, M., & Lee, K. (2025) · The Journal of Microbiology · doi:10.71150/jm.2504012 · Cited by 7
“…mechanism, clinical trials for ATTR-CM and AT-TR-PN (polyneuropathy) using a drug named NTLA-2001, developed by Intellia Therapeutics, have progressed to Phase III (NCT04601051, NCT05697861, NCT06128629, and NC06672237) (Gillmore et al., 2021; In-tellia Therapeutics, 2020, 2023a, 2023b, 2024b).”
InfluentialEmerging lipid nanoparticle systems capable of efficient intramuscular RNA delivery
Raza, A., Zhang, R., Lu, R., Wen, J., & Wu, W. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2555507 · Cited by 9
Cardiac Amyloidosis: Tribulations and New Frontiers
Nguyen, D., Ramazani, N., Sodhi, G., & Tak, T. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15100472 · Cited by 6
“In its phase 1 study, nex-z has been shown to cause few side effects in patients with hereditary ATTRv with polyneuropathy [94].”
Tang, M. J., Tay, T. Y., Gibbs, S. D., & Niewiadomski, O. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70083 · Cited by 6
A differentiated and durable allogeneic strategy applicable to cell therapies.
Jetley, U., Balwani, I., Sharma, P., Miller, I. C., Luther, A., Dutta, I., Saravanan, N., Goel, S., Zhang, Q.-Z., Zhang, B.-N., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.10.001 · Cited by 2
Transthyretin Amyloid Cardiomyopathy: The Plot Thickens as Novel Therapies Emerge
Dimza, M., Vasilakis, G., & Grodin, J. (2025) · US cardiology · doi:10.15420/usc.2025.11 · Cited by 6
Tutubala, T. E., Egunlusi, A. O., Fisher, D., Dube, A., & Joubert, J. (2025) · ACS Omega · doi:10.1021/acsomega.4c04887 · Cited by 12
Tian, W., Yu, S., Zhang, K., et al. (2025) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2025.11.003 · Cited by 5
“Owing to its base-pairing-dependent cleavage mechanism and high programmability, the CRISPR/Cas system has recently become an effective tool for gene editing and bioassays, revolutionizing biotechnology, agriculture, and medical research [6 – 8].”
Guarding the genome: strategies for off-target detection and minimization in CRISPR/Cas9 system
Lotfi, M., Yazdi, Z. F., Hashemi, M. R., Abbaszadegan, M. R., & Sharif, S. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2581677 · Cited by 8
“This advancement has already led to the development of new therapeutic candidates, some of which are currently undergoing clinical trials (NCT04601051) [110,134,135].”
Kantor, B., Duke, L. C., & Bhide, P. G. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102786 · Cited by 8
Huang, Y., Pang, S., Li, L., Do, C. W., Luo, Q., 郑宗立, & Xiong, W. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114499 · Cited by 12
Targeted Intracellular Delivery via Precision Programming of ARRDC1‐Mediated Microvesicles
Qiao, Z., Choi, S., Chen, Z., Rodriguez, R. M., Wang, Q., Yang, Z., Theuerkauf, S. A., Nabhan, J. F., Hensch, T. K., Buchholz, C. J., et al. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70199 · Cited by 7
Chakraborty, C., Bhattacharya, M., Das, A., Agoramoorthy, G., & Lee, S.-S. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102859 · Cited by 12
CRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics
Rutkowska, A., Strózik, T., Wasiak, T., Ciunowicz, D., Kapelan, N., Szczepaniak, N., Sosnowski, J., Goślińska, W., Bartkowiak, J., Budny-Lewandowska, A., et al. (2026) · Cells · doi:10.3390/cells15070644 · Cited by 5
Chien, K. R., Foo, K. S., & Witman, N. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01459-7 · Cited by 16
“…first-in-human study used an LNP for the in vivo delivery of a gene-editing payload (consisting of an mRNA encoding the Cas9 nuclease and a single guide RNA (sgRNA)) to the liver of patients harbouring mutations in the transthyretin ( TTR ) gene that cause transthyretin amyloidosis (ATTR) 167 (Fig.”
InfluentialLiu, S., Deng, S., Li, M., Chen, J., Yuan, Y., Zhao, H., Zhou, J., Wang, J., Zhang, H., & Cheng, D. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c16588 · Cited by 5
Disease‐Modifying Drugs Extend Survival in Hereditary Transthyretin Amyloid Polyneuropathy
Ueda, M., Misumi, Y., Nomura, T., Tasaki, M., Yamakawa, S., Obayashi, K., Yamashita, T., & Ando, Y. (2023) · Annals of Neurology · doi:10.1002/ana.26845 · Cited by 5
“16,17 Past clinical trials indicated that DMDs could halt progression of symptoms associated with the disease.”
BackgroundNanodelivery in Gene Therapy: Unlocking the Potential for Precision Medicine
Eksi, O. B., Kutlu, A. Ü., Yumuk, K., Memet, B. C., Benk, R., Kurşunluoğlu, G., & Aydin, Ö. F. (2024) · Springer eBooks · doi:10.1007/978-3-030-80962-1_410-1 · Cited by 7
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



